1. Home
  2. AGIO vs NNNN Comparison

AGIO vs NNNN Comparison

Compare AGIO & NNNN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Agios Pharmaceuticals Inc.

AGIO

Agios Pharmaceuticals Inc.

HOLD

Current Price

$27.18

Market Cap

1.6B

Sector

Health Care

ML Signal

HOLD

Logo Anbio Biotechnology Class A Ordinary Shares

NNNN

Anbio Biotechnology Class A Ordinary Shares

HOLD

Current Price

$33.50

Market Cap

1.5B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
AGIO
NNNN
Founded
2007
2021
Country
United States
Germany
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: In Vitro & In Vivo Diagnostic Substances
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.6B
1.5B
IPO Year
2013
2025

Fundamental Metrics

Financial Performance
Metric
AGIO
NNNN
Price
$27.18
$33.50
Analyst Decision
Buy
Analyst Count
8
0
Target Price
$36.25
N/A
AVG Volume (30 Days)
1.5M
38.1K
Earning Date
02-12-2026
04-28-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
0.06
Revenue
$44,791,000.00
$6,920,153.00
Revenue This Year
$27.83
N/A
Revenue Next Year
$134.79
N/A
P/E Ratio
N/A
$589.80
Revenue Growth
36.26
N/A
52 Week Low
$22.24
$5.18
52 Week High
$46.00
$55.65

Technical Indicators

Market Signals
Indicator
AGIO
NNNN
Relative Strength Index (RSI) 45.23 49.21
Support Level $27.30 $32.93
Resistance Level $28.87 $43.00
Average True Range (ATR) 1.00 4.09
MACD 0.30 0.00
Stochastic Oscillator 26.55 33.23

Price Performance

Historical Comparison
AGIO
NNNN

About AGIO Agios Pharmaceuticals Inc.

Agios Pharmaceuticals Inc is a biopharmaceutical company focused on the field of cellular metabolism to create differentiated medicines for rare diseases, with a focus on classical hematology. The company's primary focus is to develop potentially transformative small-molecule medicines. Its product candidate, Pyrukynd (mitapivat), is an activator of both wild-type and mutant pyruvate kinase enzymes, developed for the treatment of hemolytic anemias. The other drug candidates in its pipeline include Tebapivat (PK activator), being developed as a potential treatment for MDS-associated anemia and sickle cell disease, AG-181 (PAH stabilizer), AG-236, and others.

About NNNN Anbio Biotechnology Class A Ordinary Shares

Anbio Biotechnology is a medical device company focused on in vitro diagnostics. It offers laboratory, wellness, at-home, and point-of-care (POCT) in vitro diagnostic (IVD) solutions to detect a wide range of biomarkers associated with critical medical domains encompassing infectious diseases, cancer, cardiovascular diseases, inflammation, drug abuse, endocrine disorders, renal disease, pharmacogenomics, and diabetes. Its product portfolio comprises AF-1200 Fluorescence Immunoassay Analyzer, SHA-100 Dry Chemistry Analyzer, Ferritin Rapid Test Kit, Dengue NS1 Rapid Test, Multi-HBV Rapid Test, COVID-19 Test Kit (Real-time PCR), and others. Geographically, the company generates maximum revenue from the European Union, followed by South America, Asia Pacific, North America, and other regions.

Share on Social Networks: